MedTrace Logo

Speech Treatment for Minimally Verbal Children With ASD and CAS

NCT05066178 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-30

No results posted yet for this study

Summary

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Conditions

Interventions

BEHAVIORAL

CAS Treatment for Minimally Verbal Children with Autism

Treatment involves principles of motor learning embedded in a naturalistic developmental milieu

Sponsors & Collaborators

  • MGH Institute of Health Professions

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2030-04-30
Completion
2030-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05066178 on ClinicalTrials.gov